Skip to main content
. Author manuscript; available in PMC: 2017 Aug 8.
Published in final edited form as: Int J Eat Disord. 2010 Jul;43(5):472–479. doi: 10.1002/eat.20829

TABLE 3.

Characteristics of sample according to history of alli® use

History Use of alli® N (%)a,b or Mean ± SD (Range)b No History of Complete alli® Use N (%)a,b or Mean ± SD (Range)b Sample N (%)a,b or Mean ± SD (Range)b
N 26 (6.2) 391 (93.8) 417
Age (years) 39 ± 13.9 (15–61) 33 ± 13 (13–69) 33.2 ± 13.1 (13–69)
Age < 18 years 1 (3.8) 19 (4.9) 20 (4.8)
BMI (kg/m2) 28.8 ± 10 (14.9–44.6) 28.3 ± 11.9 (10.6–70.9) 28.3 ± 11.8 (10.6–70.9)
BMI < 25 kg/m2 10 (38.5) 194 (49.6) 204 (48.9)
Gender
 Female 22 (84.6) 346 (88.5) 368 (88.2)
 Male 1 (3.8) 34 (8.7) 35 (8.4)
Race/ethnicity
 White 17 (65.4) 311 (79.5) 328 (78.7)
 African American 5 (19.2) 30 (7.7) 35 (8.4)
 Native American 0 (0) 2 (.51) 2 (.48)
 Hispanic 3 (11.5) 29 (7.4) 32 (7.7)
 Asian 0 (0) 4 (1) 4 (1)
 Other/unknown 1 (3.8) 14 (3.6) 15 (3.6)
Eating disorder behaviors in the past monthc
 Binge eating 16 (61.5) 230 (58.8) 246 (59)
 Self-induced vomiting 10 (38.5) 137 (35) 147 (35.3)
 Laxative use 7 (26.9) 52 (13.3) 59 (14.1)
 Diet pill use 15 (57.7) 46 (11.8) 61 (14.6)
 Diuretic use 9 (34.6) 26 (6.6) 35 (8.4)
 Syrup of Ipecac use 2 (7.7) 4 (1) 6 (1.4)
 alli® use 12 (46.2) 12 (2.9)
 Herbal “fat burner” use 10 (38.5) 56 (14.3) 66 (15.8)
a

Percentages in each column were computed as the number of positive responses divided by the total sample in the respective alli® use group or the complete sample (N = 26, N = 391, or N = 417). Only participants who responded to the question asking if they had ever used alli® are included.

b

Values based upon available data; not all participants completed all questions.

c

Missing data were treated as a negative response to the question.